Please assess the completion status of the following clinical trial:

Trial Title: Growth Hormone's Effect on the Cardiovascular System

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Adult between the ages of 18 and 65~* Documented Growth Hormone Deficiency as defined by a peak Growth Hormone during a GHRH-Arginine Stimulation test not exceeding 9.5 ng/ml~Exclusion Criteria:~* Personal history of cardiovascular disease (previous myocardial infarction or known coronary artery disease) or diagnosis of heart disease between study visits.~* Personal history of diabetes mellitus or development of diabetes between study visits.~* Initiation of an anti-cholesterol medication or anti-hypertensive between baseline and follow-up study visit.~* Initiation of regular tobacco use between baseline and follow-up study visit.~* Pregnancy or nursing~* Current daily use of any drug known to affect the fibrinolytic system: Aspirin, Aggrenox, Plavix, Persantine, Ticlid, Pletal, Trental, Lovenox, Coumadin, Agrylin, and Hydroxyurea.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).